First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Recruiting · Phase 1 · NCT06644755
Conditions: Solid Tumors, Sarcoma
At a glance
- Research payments reported, 2025
- $315,088
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 150
About the trial
- Sponsor
- Daiichi Sankyo
- Tested
- DS-2243a (drug)
- Dates
- Started 2024-11-14; completion 2028-11-30
- Results posted
- Not yet
This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.
From ClinicalTrials.gov, last updated 2026-09-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $315,088 in research payments for this study in 2025 (28 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Vivek Subbiah, MD Medical Oncology · Stanford, CA
- Michael J. Wagner Medical Oncology · Boston, MA
- Sandra P. Dangelo, MD Medical Oncology · New York, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $172,213
- David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center $77,525
- Sarah Cannon Research Institute $65,350
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.